Vaginal lactoferrin administration before genetic amniocentesis decreases amniotic interleukin-6 levels

Gynecologic and Obstetric Investigation

Volumn 77, Issue 4, 2014, Pages 245-249

  Vesce, Fortunato ^a   Giugliano, Emilio ^a   Bignardi, Stefania ^a   Cagnazzo, Elisa ^a   Colamussi, Cecilia ^a   Marci, Roberto ^a   Valente, Nicoletta ^b   Seraceni, Silvia ^b   Maritati, Martina ^b   Contini, Carlo ^b  

^a Departments of Obstetrics and Gynecology   (Italy)

^b UNIVERSITY OF FERRARA   (Italy)

Author keywords

Abortion; Amniocentesis; Interleukin 6; Lactoferrin

Indexed keywords

CYTOKINE; GLYCOPROTEIN; INTERLEUKIN 6; LACTOFERRIN; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; BIOLOGICAL MARKER;

ABORTION; ADULT; AMNIOCENTESIS; ARTICLE; CAUCASIAN; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; FEMALE; GENETIC ANALYSIS; GESTATIONAL AGE; HUMAN; IMMUNOASSAY; KARYOTYPE; PREGNANCY; PREGNANCY COMPLICATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; TISSUE LEVEL; AMNION FLUID; DRUG ADMINISTRATION; DRUG EFFECTS; INTRAVAGINAL DRUG ADMINISTRATION; METABOLISM; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; SECOND TRIMESTER PREGNANCY; DRUG EFFECT; DRUG EFFICACY; LIMIT OF DETECTION; PROTEIN EXPRESSION; STATISTICAL ANALYSIS;

ADMINISTRATION, INTRAVAGINAL; ADULT; AMNIOCENTESIS; AMNIOTIC FLUID; ANTI-INFECTIVE AGENTS; ANTI-INFLAMMATORY AGENTS; BIOLOGICAL MARKERS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INTERLEUKIN-6; LACTOFERRIN; PATIENT OUTCOME ASSESSMENT; PREGNANCY; PREGNANCY TRIMESTER, SECOND;

EID: 84903733270     PISSN: 03787346     EISSN: 1423002X     Source Type: Journal    
DOI: 10.1159/000358877     Document Type: Article

References (36)

1. Xing Z, Gauldie J, Cox G, Baumann H, Jor-dana M, Lei XF, Achong MK: IL-6 is an anti-inflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Invest 1998; 101:311-320. (Pubitemid 28067327)
2. Hurst SM, Wilkinson TS, McLoughlin RM, Jones S, Horiuchi S, Yamamoto N, Rose-John S, Fuller GM, Topley N, Jones SA: Control of leukocyte infiltration during inflammation: IL-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment. Immunity 2001; 14:705-714. (Pubitemid 32592418)
3. Wenstrom KD, Andrews WW, Tamura T, DuBard MB, Johnston KE, Hemstreet GP: Elevated amniotic fluid interleukin-6 levels at genetic amniocentesis predict subsequent pregnancy loss. Am J Obstet Gynecol 1996; 175:830-833. (Pubitemid 26357937)
4. Bogavac M, Brkic S, Simin N, Celic D: Mid-pregnancy interleukin levels in serum and amniotic fluid as predictors of preterm delivery. J Matern Fetal Neonatal Med 2012, Epub ahead of print.
5. Xiao JP, Yin YX, Gao YF, Lau S, Shen F, Zhao M, Chen Q: The increased maternal serum levels of IL-6 are associated with the severity and onset of preeclampsia. Cytokine 2012; 60: 856-860.
6. 2 release by ampicillin. Obstet Gynecol 2004; 103:108-113. (Pubitemid 39248475)
7. Paesano R, Berlutti F, Pietropaoli M, Gools-bee W, Pacifici E, Valenti P: Lactoferrin efficacy versus ferrous sulfate in curing iron disorders in pregnant and non-pregnant women. Int J Immunopathol Pharmacol 2010; 23: 577-587.
8. Levay PF, Viljoen M: Lactoferrin: a general review. Haematologica 1995; 80:252-267.
9. Niemela A, Kulomaa M, Vilja P, Tuohimaa P, Saarikoski S: Lactoferrin in human amniotic fluid. Hum Reprod 1989; 4:99-101. (Pubitemid 19069919)
10. Nappi C, Tommaselli GA, Morra I, Massaro M, Formisano C, Di Carlo C: Efficacy and tol-erability of oral bovine lactoferrin compared to ferrous sulfate in pregnant women with iron deficiency anemia: a prospective controlled randomized study. Acta Obstet Gyne-col Scand 2009; 88:1031-1035.
11. Lee SY, Buhimschi IA, Dulay AT, Ali UA, Zhao G, Abdel-Razeq SS, Bahtiyar MO, Thung SF, Funai EF, Buhimschi CS: IL-6 trans-signaling system in intra-amniotic inflammation, preterm birth, and preterm premature rupture of the membranes. J Immunol 2011; 186:3226-3236.
12. Challis JR, Lockwood CJ, Myatt L, Norman JE, Strauss JF 3rd, Petraglia F: Inflammation and pregnancy. Reprod Sci 2009; 16:206-215.
13. Paulesu L, Bhattacharjee J, Bechi N, Roma-gnoli R, Jantra S, Ietta F: Pro-inflammatory cytokines in animal and human gestation. Curr Pharm Des 2010; 16:3601-3615.
14. Lunghi L, Pavan B, Biondi C, Paolillo R, Vale-rio A, Vesce F, Patella A: Use of glucocorti-coids in pregnancy. Curr Pharm Des 2010; 16: 3616-3637.
15. Suzuki Y, Yamamoto T, Kojima K, Tanemura M, Tateyama H, Suzumori K: Evaluation of levels of cytokines in amniotic fluid of women with intrauterine infection in the early second trimester. Fetal Diagn Ther 2006; 21:45-50. (Pubitemid 41803423)
16. Dudley DJ: Pre-term labor: an intra-uterine inflammatory response syndrome? J Reprod Immunol 1997; 36:93-109. (Pubitemid 27511461)
17. Goldenberg RL, Culhane JF, Iams JD, Romero R: Epidemiology and causes of preterm birth. Lancet 2008; 371:75-84.
18. Romero R, Gomez R, Ghezzi F, Yoon BH, Mazor M, Edwin SS, Berry SM: A fetal systemic inflammatory response is followed by the spontaneous onset of preterm parturition. Am J Obstet Gynecol 1998; 179:186-193. (Pubitemid 28394494)
19. Akira S, Taga T, Kishimoto T: Interleukin-6 in biology and medicine. Adv Immunol 1993; 54:1-78. (Pubitemid 23289250)
20. Lee SE, Romero R, Park CW, Jun JK, Yoon BH: The frequency and significance of intra-amniotic inflammation in patients with cervical insufficiency. Am J Obstet Gynecol 2008; 198:633.
21. Engel SA, Erichsen HC, Savitz DA, Thorp J, Chanock SJ, Olshan AF: Risk of spontaneous preterm birth is associated with common pro-inflammatory cytokine polymorphisms. Epidemiology 2005; 16:469-477. (Pubitemid 40847830)
22. Holst D, Garnier Y: Preterm birth and inflammation-the role of genetic polymorphisms. Eur J Obstet Gynecol Reprod Biol 2008; 141: 3-9.
23. Annells MF, Hart PH, Mullighan CG, Heatley SL, Robinson JS, McDonald HM: Polymorphisms in immunoregulatory genes and the risk of histologic chorioamnionitis in Cauca-soid women: a case control study. BMC Pregnancy Childbirth 2005; 5:4.
24. Song C, Xie S, Wang J, Lian J, Diao B, Tang Y: Association of angiotensinogen gene polymorphisms and angiogenic factors with pre-eclampsia in Chinese women. Gynecol Obstet Invest 2013; 76:64-68.
25. Gomez R, Romero R, Ghezzi F, Yoon BH, Mazor M, Berry SM: The fetal inflammatory response syndrome. Am J Obstet Gynecol 1998; 179:194-202. (Pubitemid 28394495)
26. Sado T, Kitanaka T, Naruse K, Oi H, Noguchi T, Yoshida S, Kajihara H, Shigetomi H, Oono-gi A, Kobayashi H: Anticytokine therapy in preterm labor: current knowledge and future perspectives. Gynecol Obstet Invest 2011; 71: 1-10.
27. Vesce F, Buzzi M, Ferretti ME, Pavan B, Bian-ciotto A, Jorizzo G, Biondi C: Inhibition of amniotic prostaglandin E release by ampicil-lin. Am J Obstet Gynecol 1998; 178:759-764. (Pubitemid 28196884)
28. Vesce F, Pavan B, Buzzi M, Pareschi MC, Bi-anciotto A, Iorizzo G, Biondi C: Effect of different classes of antibiotics on amniotic pros-taglandin E release. Prostaglandins Other Lipid Mediat 1999; 57:207-218. (Pubitemid 29323625)
29. Tabor A, Vestergaard CH, Lidegaard Ø: Fetal loss rate after chorionic villus sampling and amniocentesis: an 11-year national registry study. Ultrasound Obstet Gynecol 2009; 34: 19-24.
30. Giorlandino C, Cignini P, Cini M, Brizzi C, Carcioppolo O, Milite V, Coco C, Gentili P, Mangiafico L, Mesoraca A, Bizzoco D, Gabri-elli I, Mobili L: Antibiotic prophylaxis before second-trimester genetic amniocentesis (APGA): a single-centre open randomised controlled trial. Prenat Diagn 2009; 29:606-612.
31. Seeds JW: Diagnostic mid trimester amnio-centesis: how safe? Am J Obstet Gynecol 2004; 191:607-615.
32. González-Chávez SA, Arévalo-Gallegos S, Rascón-Cruz Q: Lactoferrin: structure, function and applications. Int J Antimicrob Agents 2009; 33:301.
33. Actor JK, Hwang SA, Kruzel ML: Lactoferrin as a natural immune modulator. Curr Pharm Des 2009; 15:1956-1973.
34. Otsuki K, Yoda A, Toma Y, Shimizu Y, Saito H, Yanaihara T: Lactoferrin and interleukin-6 interaction in amniotic infection. Adv Exp Med Biol 1998; 443:267-271. (Pubitemid 28432196)
35. Heller KA, Greig PC, Heine RP: Amniotic-fluid lactoferrin: a marker for subclinical in-tra-amniotic infection prior to 32 weeks gestation. Infect Dis Obstet Gynecol 1995; 3:179-183. (Pubitemid 26174017)
36. Nojima Y, Suzuki Y, Yoshida K, Abe F, Shiga T, Takeuchi T, Sugiyama A, Shimizu H, Sato A: Lactoferrin conjugated with 40-kDa branched poly(ethylene glycol) has an improved circulating half-life. Pharm Res 2009; 26:2125-2132.